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INTRODUCTION 
 
NATURE AND CURRENT EXPLANATIONS OF HUMAN CANCERS 
Literally, "neoplasm" means "new growth". One of the most cited definition of 
tumor is that given from the British pathologist R.A. Willis, in 1952: "A 
neoplasm is an abnormal mass of tissue, the growth of which exceeds and is 
uncoordinated with that of the normal tissues, and persists in the same 
excessive manner after cessation of the stimulus which evoked the change" 
(Willis, 1952). 
From an histopathological point of view, tumors often retain the distinctive 
structures that characterize the tissue/organ of origin. Solid tumors tipically 
contain a parenchyma of proliferating neoplastic cells and a supporting tissue, 
or stroma.  
 
Because tumor size typically increases with time, pathologists have postulated 
that the underlying cause of tumor formation must have been excessive cell 
proliferation in the parenchyma (Willis, 1967). Within this conceptual frame, 
cancer has been interpreted as a cell-centered problem, and hence, the aim of 
cancer research has been to understand how a normal cell becomes a cancer 
cell. However, as Boveri already remarked in 1914, a major problem in the 
study of carcinogenesis is that it is not possible to identify a neoplasm "in statu 
nascendi". Consequently, different theories of carcinogenesis have emerged. 
Most of them centered at the cellular level of biological organization and 
described cancer as a problem of cell proliferation or cell differentiation. 
Others, by contrast, focused on the tissue level of biological organization.  
In this context, the somatic mutation theory of carcinogenesis (SMT) has been 
the prevailing paradigm in cancer research for the last 50 years (Curtis, 1965). 
Its main premise is that cancer derives from a single somatic cell that has 
accumulated multiple DNA mutations over time. This implies that cancers are 
monoclonal, deriving from aberrant proliferation of a single mutated cell 
(Weinberg, 1998). A second implicit premise is that the default physiological 
condition of cells in multicellular organisms is quiescence, where "default 
state" means the state in which cells are found when they are freed from any 
active control (Alberts, 2002). A third premise of this theory considers that 
cancer is a disease of cell proliferation and that cancer-causing mutations 
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occur in genes that control cell proliferation and/or the cell cycle (Alberts, 
2001).  
The rise of the SMT as the mainstream theory of carcinogenesis was supported 
by the following findings: (i) a considerable number of carcinogenic chemicals 
were found to be mutagenic; (ii) specific viral genes enabled in vitro cell 
transformation and development of tumors after injection in some animal 
models; (iii) DNA fragments from chemically transformed cells were in turn 
able to transform recipient normal cells and the DNA sequences involved were 
identified as mutated versions of endogenous genes (the so-called proto-
oncogenes). Thus, oncogenes were considered to host "gain of function" 
mutations that led the cells to enhanced and de-regulated proliferation.  
However, the study of rare hereditary cancers, representing 5% of all human 
tumors, revealed that the DNA defects transmitted along the germ line were 
due to deletions in specific genes. Unlike the case of oncogenes, these 
deletions implied a "loss of function". The first of these anti-oncogenes (later 
re-named "tumor suppressor genes") was retinoblastoma (RB) gene, that was 
soon implicated in cell cycle regulation.   
 
Many different types of genetic variation can indeed influence the propensity 
for neoplastic transformation of a normal cell. They are known to influence 
DNA repair, cell cycle-checkpoints control, epigenetic imprinting or apoptotic 
proneness (Hanahan, 2000). Six hallmarks of cancer have been proposed by 
Hanahan and Weinberg in 2000 (Hanahan, 2000), which represent distinctive 
capabilities of tumor cells that enable tumor growth and metastatic 
dissemination.  
The most important trait of cancer cells is their ability to sustain chronic 
proliferation. Indeed, tumor cells can (i) produce growth factors themselves 
and (ii) send signals to the supporting stroma inducing production of growth 
factors (Bhowmick, 2004). Alternatively, receptor signaling can be de-regulated 
by the overexpression of receptor proteins or by the constitutive activation of 
signaling pathways operating downstream of these receptors (Lemmon, 2010).  
A second hallmark of tumor cells is their ability to evade programs that 
negatively regulate cell proliferation. Many of these programs depend on the 
action of tumor suppressor genes. The two prototypical anti-oncogenes 
encode the retinoblastoma-associated (RB) and the TP53 proteins, which 
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operate within the regulatory circuits that govern the decision of a cell to 
proliferate or, alternatively, activate senescence and apoptotic death programs 
(Sherr, 2002).  
Third, tumor cells acquire the ability to escape programmed cell death by 
apoptosis, which is a natural barrier to cancer development. Cancer cells have 
evolved a lot of different strategies to circumvent apoptosis. Once again, most 
common is the loss of the critical damage sensor TP53, but the same result 
may be achieved by either overexpressing anti-apoptotic regulators (Bcl-2, Bcl-
xL) or downregulating pro-apoptotic factors (Bax, Bim, Puma) (Evan, 1998).    
Cancer cells also require unlimited replicative potential in order to generate 
tumors. Normal cells are able to pass through only a limited number of 
divisions and then enter senescence. The immortalization of tumor cells is due 
to their ability to maintain telomeric DNA at lengths sufficient to avoid 
triggering senescence or apoptosis; this is achieved by upregulating expression 
of telomerase or, less frequently, by an alternative recombination-based 
telomere maintenance mechanism (Shay, 2000).   
Moreover, like normal tissues, tumors require nutrient and oxygen supplies as 
well as the ability to eliminate metabolic wastes and carbon dioxide. Thus, 
during tumor progression an angiogenic switch is activated, causing normally 
quiescent vascolature to continually sprout new vessels that help sustaining 
tumor growth (Hanahan, 1996).  
Finally, tumor cells often acquire the ability to locally invade tissues and/or 
metastasize. Typically, alterations in cancer cell shape as well as in attachment 
to other cells and to the extracellular matrix occur. The invasion-metastasis 
cascade seems to involve discrete steps: (i) local invasion, (ii) intravasation into 
nearby blood and lymphatic vessels, (iii) transit through the lymphatic and 
hematogenous systems, (iv) extravasation, (v) micrometastases formation and 
(vi) colonization with development of macroscopic tumors (Talmadge, 2010).    
Recently, two other distinctive characteristics of cancer cells have been 
proposed to be functionally important for tumor development and might 
therefore be added to the list of core hallmarks (Hanahan, 2011). The first 
involves reprogramming of cellular energy metabolism in order to support 
continuous cell growth and proliferation. The second involves active evasion 
by cancer cells from attack and elimination by immune cells.  
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Although the majority of carcinogenesis theories are strictly cancer cell-
centered, in recent years tumors have increasingly been recognized as organs 
whose complexity must be taken into account to understand tumor biology. 
Oncogenes and tumor suppressor genes are highly conserved in all mammals, 
as well as the pathways in which they are involved. If their pro-oncogenic 
mutation would be the rate-limiting step in tumor development, the frequency 
of tumors might be expected to increase with the number of cells in an animal. 
We know this is not the case. This concept is known as "Peto's paradox": a 
huge animal like the whale, that has 1017 total cells, doesn't have more but 
rather less tumors than the mouse, with 109 total cells.  
Moreover, in view of the large number of genetic and epigenetic changes that 
can initiate and promote tumor development, cancer can be seen nevertheless 
as a relatively rare disease. Two of three people never develop clinically 
manifest cancer and even the majority of heavy smokers remain tumor-free 
(Klein, 2007). These and other similar observations suggest the presence of a 
systemic control which plays an important role in tumor development. Within 
this framework, the reductionist view of the tumor as a collection of cancer 
cells must be revised and the biology of tumor development should be 
investigated in the context of the tumor microenvironment (Hanahan, 2011).  
From a theoretical point of view, among the proposed organicist theories of 
carcinogenesis, the tissue organization field theory (TOFT) is the most known 
and evidence-supported. The TOFT is based on two main premises, which are 
not compatible with those proposed in the SMT: (i) proliferation rather than 
quiescence is the default state of cells in multicellular organisms and (ii) 
carcinogenesis acts initially by disrupting the normal interactions that take 
place among cells which compose the stroma and parenchyma of an organ 
(Sonnenschein, 2000).  
In carcinomas and adeno-carcinomas, which represent the majority of human 
neoplasms, the proposed model is that disruption of these interactions allows 
the epithelial cells to exercise their constitutive property to proliferate 
(hyperplasia). Next, the tissue organizational pattern would become altered 
(dysplasia), leading to carcinoma in situ formation. Within this framework, 
somatic mutations might represent an epiphenomenon and don't have a 
causal role in tumor initiation and progression. 
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Central to this dynamic process is its reversibility (Clark, 1991). The neoplastic 
phenotype can be experimentally reversed through cell-cell interactions as 
demonstrated for embryonal carcinoma cells injected into blastocysts 
(Illmensee, 1976), hepatocellular carcinoma cells injected into normal livers 
(McCullough, 1998), or by modification of the extracellular matrix components 
(Bissell, 2001). Of course, this reversibility negatively correlate with both the 
tumor stage and the severity of the histoarchitecture compromission.   
Because of the high grade of heterogeneity within both the tumor mass and 
the stromal compartment, little is known about the mechanisms that govern 
the interactions between cancer cells and the microenvironment. Different cell 
types are known to be present in the tumor surroundings: fibroblasts (cancer-
associated fibroblasts, CAFs), endothelial cells, pericytes, immune 
inflammatory cells (tumor-associated macrophages, TAMs) and progenitor 
cells of the tumor stroma. All of these cells could have either a promoting or an 
inhibitory activity on tumor growth, depending on the presence of specific 
signaling molecules which induce different cell polarization (Hanahan, 2011).  
The documented genetic instability of tumor cells, coupled with their rapid 
replication, results in the emergence of resistant clones under the selective 
pressure of conventional cytotoxic therapy. By contrast, the non-neoplastic 
stromal cells do not display marked genetic instability, thus being a better 
target for anti-cancer therapy (Tarin, 2012). Within this framework, the 
detailed investigation of the molecular interplay between cancer cells and 
tumor microenvironment is mandatory because of its important therapeutic 
implications. 
 
ROLE OF THE RNASET2 GENE IN HUMAN CANCERS 
In the past two decades, a solid body of epidemiological data was collected 
reporting associations between chromosomic alterations in the peritelomeric 
region of the long arm of human chromosome 6 and a wide range of solid and 
hematological tumors, i.e. ovarian carcinoma (Saito, 1992) (Tibiletti, 1996), 
breast cancer (Chappell, 1997), endometrial cancer (Tibiletti, 1997), gastric 
carcinoma (Queimado, 1995), hepatocellular tumor (Souza, 1995), colorectal 
cancer (Honchel, 1996), renal cell carcinoma (Morita, 1991), melanoma 
(Millikin, 1991), B-cell non-Hodgkin lymphoma (Gaidano, 1992) and acute 
lymphoblastic leukemia (Hayashi, 1990).  
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Particularly, researchers have put a lot of efforts into investigation of 
molecular mechanisms which subtend ovarian cancers growth. From an 
epidemiological point of view, ovarian cancer is the most lethal gynecological 
cancer. Ovarian carcinomas, accounting for 90% of all ovarian tumors, are a 
heterogeneous group of neoplasms. Pathologists currently employ a 
morphology-based classification system to divide ovarian carcinomas into four 
major subgroups, based on tumor grade and type of differentiation: serous 
(70%), endometrioid (10-15%), clear cell (10%) and mucinous (3%) carcinomas 
(Cho, 2009). Currently, very little is known about how the cancer initiates and 
progresses. The ovary has long been considered the primary origin of this 
tumor. However, precursor lesions have not been identified in the ovary and 
new evidence has emerged to propose the fallopian tube as a different source 
of ovarian cancer (Kurman, 2010) (Crum, 2007). Within this frame, uncovering 
the molecular pathways involved in ovarian carcinoma initiation and 
progression could improve diagnostic success and consequently reduce death 
rate. 
Loss of heterozygosity (LoH) studies have been conducted in the last decades 
on ovarian tumors and ovarian cancer cell lines, showing LoH regions on 
human chromosomes 1, 6, 9, 10 and 11 (Nakayama, 2007) (Tapper, 1997) 
(Suehiro, 2000). Particularly, three different consensus regions of loss in 
human chromosome 6 were identified: 6q21-23.3 (Orphanos, 1995), 6q25.1-
25.2 (Colitti, 1998) and 6q.26-27 (Saito, 1992) (Tibiletti, 1996). The human 
RNASET2 gene maps within the latter chromosomic region. It spans 27 kb, it is 
a single-copy gene and it is composed by nine exons and eight introns (Tibiletti, 
1998). It codes for the unique human member of the extracellular Rh/T2/S 
ribonuclease family. T2 RNases are ubiquitous highly evolutionary-conserved 
glycoproteins endowed with multiple biological functions in diverse organisms 
(McClure, 1990).  
The human RNASET2 protein is composed by 256 aminoacids and primary 
sequence analysis revealed the presence of three distinct protein segments: (i) 
a signal peptide for secretion at the N-terminus (aa. 1-24), (ii) a central core 
that undergoes N-glycosilation and in which resides the two conserved active-
site segments (CASI and CASII) indispensable for the catalitic activity of the 
protein and (iii) a C-terminal de-structured portion (Campomenosi, 2006). 
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RNASET2 protein exists in three different intracellular isoforms: the full-lenght 
36 kDa form, which is the only one secreted in the extracellular space, and the 
31 and 27 kDa isoforms, which originate from proteolytic cleaveges at the C-
terminus of the full-lenght protein. A sub-cellular fractionation experiment in 
RNASET2-overexpressing HEY4 cells has shown that both the 31 and the 27 
kDa forms were present in the lysosomal fraction. This observation is 
consistent with the hypothesis of a functional role of RNASET2 as an acid 
ribonuclease in the acid lysosomal compartment (Campomenosi, 2006). As for 
the ribonuclease activity of RNASET2 protein, it shows a base preference for 
poly-A and poly-U syntetic polynucleotides, with respect to poly-G and poly-C, 
at pH 5.0 (Campomenosi, 2006).  
 
Because of the chromosomic location of human RNASET2 gene in a region 
frequently rearranged in tumors, we investigated the putative tumor 
suppressive role of this gene. 
Using the ovarian carcinoma as an experimental model, no mutations were 
found in the coding sequence of the RNASET2 gene in human primary ovarian 
tumors and tumor cell lines (Acquati, 2001). Nevertheless, RNASET2 down-
regulation at the mRNA level was reported in both primary ovarian tumors and 
ovarian tumor cell lines, with respect to normal tissue/cells. In order to 
understand the cause of the lower RNASET2 expression levels in tumors, a 
promoter methylation analysis was performed. As a result, no significant 
differences in promoter methylation were reported between tumor and 
normal samples, suggesting that other epigenetic mechanisms could be 
responsible for RNASET2 hypoexpression in tumors (Acquati, 2001).  
Using both ovarian carcinoma and malignant melanoma as experimental 
models, we have demonstrated a marked RNASET2-mediated tumor 
suppression in vivo. Indeed, RNASET2-overexpressing tumor clones turned out 
to be strongly suppressed in their tumorigenic and metastatic potential after 
injection in immunodeficient mice (Acquati, 2001) (Monti, 2008). 
On the basis of this evidence, we can consider RNASET2 as a class II tumor 
suppressor gene: it is hypoexpressed in tumors, despite the absence of 
structural alterations in the sequence of the gene. 
To address the role of the catalytic activity of RNASET2 protein in the observed 
in vivo tumor suppression, Hey3Met2 ovarian tumor clones overexpressing a 
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catalytically inactive form of the protein were generated. The catalytically-
dead form of the protein was obtained by replacement of the two key 
Histidine residues in CAS sytes (H65 and H118) with two Phenylalanine 
residues.   
Strikingly, RNASET2-mediated tumor suppression turned out to be 
independent of the ribonuclease activity of the protein. Indeed, using 
xenograft models in nude mice, RNASET2 H65/118F-overexpressing Hey3Met2 
clones resulted to be suppressed in their tumorigenicity as well as their 
RNASET2 wild type-overexpressing counterpart (Acquati, 2005).  
Moreover, a close histological examination of xenograft tumors sections 
revealed a consistent infiltrate of host cells in tumors derived from the 
injection of RNASET2-overexpressing Hey3Met2 clones. Further histological 
analysis with specific cell-surface markers demonstrated that the monocyte-
macrophage cell lineage was predominant in this infiltrate. Particularly, M1-
polarized macrophages, which have an anti-tumoral activity, were more 
represented than M2-polarized macrophages, which have a pro-tumoral 
activity (Acquati, 2011).  
To further investigate the role of the monocyte-macrophage cell population in 
the RNASET2-mediated tumor suppression, we employed a new experimental 
model in vivo, in which the monocyte-macrophage lineage was depleted by 
clodronate treatment in RAG-γ chain mice. We observed that the RNASET2-
mediated tumor suppression activity was drastically impaired in clodronate-
treated mice if compared to the untreated control mice (Acquati, 2011). 
According to this view, the tumor microenvironment and particularly the 
monocyte-macrophage cell population seems therefore to play a crucial role in 
RNASET2-mediated tumor suppression that we have demonstrated to occur in 
vivo.            
Supporting this hypothesis, a significant body of evidence has been recently 
collected strongly suggesting a role for T2 RNases in innate immune response. 
As an example, the T2 ribonuclease omega-1 secreted from Schistosoma 
mansoni eggs has been found to be the major soluble factor in conditioning 
dendritic cells (DCs) to promote Th2 lymphocyte differentiation (Steinfelder, 
2009).  
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In spite of this strong tumor suppression activity in vivo, RNASET2 
overexpression in tumor cells seems to have no effect on several in vitro 
cancer-related parameters, such as proliferation rate, clonogenic capability, 
cell-adhesion, apoptotic rate and anchorage-independent growth (Acquati, 
2011).  
Within this atypical framework, RNASET2 could be ranked in the novel class of 
“tumor antagonizing genes” or “malignancy suppressor genes” (Islam, 2000). 
These genes are endowed with an asymmetric tumor suppressive function, 
carried out in vivo but not in vitro. Most importantly, central to their anti-
tumor function is the interaction with the tumor microenvironment, which 
plays a pivotal role in the in vivo tumor suppression (Klein, 1976).  
 
T2 FAMILY OF RIBONUCLEASES AND STRESS-RESPONSE 
Ribonucleases (RNases) are ubiquitous enzymes whose main function is RNA 
metabolism. Being involved in a wide range of important and conserved 
cellular functions, RNases are ancestral enzymes with a pivotal role in 
determining cell life or death.  
Recently, a number of genome sequencing projects have highlighted the 
presence of several non-coding RNAs which are frequently involved in both the 
regulation of gene expression and the control of cell proliferation, 
differentiation and development (Mattick, 2004). Consequently, RNases too 
were supposed to have an important role in such biological processes. Indeed, 
the human RNases Onconase and BS-RNase have proven to be strong 
inhibitors of cell proliferation and the former has been included in clinical trials 
for the treatment of mesothelioma, a rare tumor with no effective treatments 
to date (Ardelt, 1991) (D'Alessio, 1993). Within this framework, RNases could 
be an important part of novel therapeutical strategies for treatment of tumors. 
 
Traditionally, ribonucleases are classified on the basis of their base specificity, 
structure, function, optimal pH for activity and origin. Following the most 
common categorization criteria, RNases are classified as basic or acid. In the 
first group we find T1-RNase and A-RNase families, while in the second group 
we find almost only the T2-RNase family (Irie, 1999).  
RNases belonging to the T2 family are endoribonucleases either located in 
cellular compartments involved in the secretory pathway or secreted directly 
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from the cells (Deshpande, 2002). The name "T2" originated from an RNase of 
Aspergillus oryzae that was discovered by Sato and Egami (Sato, 1975), who 
proposed a mechanism for T2 RNases that released 3'-adenylic acid from RNA 
degradation. Enzymes of the T2 family have a molecular mass around 25 kDa 
and they generally have no base specificity (Irie, 1999). In their protein 
structure, all members of this family contain two highly-conserved active-site 
segments (CAS I and CAS II) which are indispensable for the catalytic activity of 
these enzymes (Mattick, 2004).  
 
A member of the T2 family of ribonucleases can be found in almost every 
organism examined including plants, fungi, bacteria, viruses and animals 
(Deshpande, 2002). This high rate of conservation throughout evolution 
suggests that these ribonucleases could have an important ancestral function. 
Moreover, due to gene duplication events occured during evolution, many 
organisms possess multiple T2 ribonuclease genes, which have diverged to 
take on specialized functions (Taylor, 1991).  
T2 RNases are involved in a wide range of activity and their sub-cellular 
location is also extremely variable: lysosomes, vacuoles, free cytoplasm and 
nucleus (Deshpande, 2002).  
Some plant ribonucleases of the T2 family have been well characterized. In 
tomato, two S-like RNases (RNaseLE and RNaseLX) have shown 
hyperexpression at both the mRNA and the protein levels during senescence 
(Lers, 2006). Another S-like RNase, AhSL28 from Anthirrhinum, increases with 
both senescence and phosphate starvation treatments (Liang, 2002). RNaseLE 
in tomato, RNS1 in Arabidopsis and RNaseNW in tobacco are also induced in 
response to wounding and during pathogen attack, suggesting an ancestral 
role for these enzymes in general stress-response and defence (Kariu, 1998) 
(Kock, 2004) (Kurata, 2002).  
Orthologues of T2 RNases have been found in organisms beside plants. As well 
as plant enzymes, however, they were also found to be involved in stress-
response processes.  
In response to environmental stress, eukaryotic cells reprogram their 
translational machinery to allow the selective expression of proteins required 
for viability in the face of changing conditions. During stress, mRNAs encoding 
constitutively expressed "housekeeping" proteins are redirected from 
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polysomes to discrete cytoplasmic foci known as "stress granules" (SGs), a 
process that is synchronous with stress-induced translational arrest (Anderson, 
2002). mRNAs within SGs are not degraded, making them available for rapid 
translation re-initiation in cells that recover from stress. Although this process 
of stress-induced mRNA stabilization is poorly understood, it likely involves the 
inactivation of one or more mRNA decay pathways. Two major mechanisms of 
mRNA degradation are active in eukaryotic cells. In the first pathway, 
deadenylated transcripts are degraded by a complex of 3'-5' exonucleases 
known as the exosome (Decker, 2002). The second pathway entails the 
removal of the 7-methyl-guanosine cap from the 5'-end of the transcript by the 
DCP1-DCP2 complex, allowing 5'-3' exonucleolytic degradation by XRN1. In 
yeast, but data were confermed also in mammalian cells, components of the 
5'-3' decay pathway are concentrated at discrete cytoplasmic foci known as 
"processing bodies" (PBs) (Sheth, 2003).   
Recent studies have described a novel aspect of stress-induced response in 
eukaryotic cells wherein cytosolic tRNAs are separated into half molecules by 
cleavage in the anticodon loop. Such mechanism has been observed in plant, 
yeast and human systems, in particular during oxidative stress (Thompson, 
2008). Interestingly, T2 ribonucleases has shown to take part to this stress-
response strategy. 
As an example, the T2 RNase Rny1p from Saccharomyces cerevisiae has been 
shown to cleave tRNAs during periods of oxidative stress (MacIntosh, 2001); in 
fact, during treatment this RNase was released from the vacuole and cleaved 
tRNAs only in the affected cells (Thompson, 2009). When Rny1p was 
overexpressed in yeast cells, the latter developed an hypersensitivity to 
oxidative stress which led to reduced viability. Surprisingly, this death-
promoting function of Rny1p turned out to be independent of its catalytic 
activity. More surprisingly, human RNASET2 overexpression in yeast cells led to 
reduced viability, too (Thompson, 2009). Within this framework, increasing 
cytoplasmic Rny1p would be a stress signal to the cell. Following a small Rny1p 
increase, tRNAs destruction might be sufficient for stress relief. By contrast, 
following a more prominent increase, cell-death program is triggered.  
 
As is widely recognized, stress, in particular metabolic stress, is of paramount 
importance for cancer initiation and progression. As an example, tumor cells 
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have to cope with acidification of both the intra- and the extra-cellular 
environments, with nutrient deprivation and with hypoxia (Hanahan, 2011). 
There is plentiful scientific literature reporting human tumor suppressor genes 
which play a pivotal role in stress-response: TP53 is among the most known 
(Schetter et al., 2012).  
Within this framework, we set up to define whether human RNASET2 also 
plays a role in stress-response in mammalian cells. While investigating the 
intracellular trafficking of RNASET2, we have recently found that the protein 
shows co-localization with processing-bodies upon metabolic stress (Vidalino, 
2012). This is the first evidence for a putative RNASET2 involvement in RNA 
metabolism in response to stress conditions. 
 Aim of the Project 
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AIM OF THE PROJECT 
The human RNASET2 gene maps in 6q27, a chromosomal region which has 
been frequently found to be deleted or rearranged in a wide range of solid and 
hematological tumors. Using ovarian carcinoma as an experimental model, we 
have demonstrated a role for this gene in tumor suppression. Indeed, in vivo 
xenograft models in immunodeficient mice have revealed a significant 
RNASET2-mediated suppression of tumorigenicity, which was not dependent 
on the ribonuclease activity of the protein. On the other hand, we found that 
the overexpression of RNASET2 in ovarian tumor cell lines had no effect on 
several in vitro cancer-related parameters. We thus ranked RNASET2 in the 
class of “tumor antagonizing genes” or “malignancy suppressor genes”, whose 
function is carried out only in vivo and it is mainly related to the tumor 
microenvironment. Within this conceptual framework, a close histological 
examination revealed a consistent infiltrate of host macrophages in xenograft 
tumors derived from the injection of RNASET2-overexpressing tumor clones. In 
the attempt to gain more insights into this microenvironmental contribution to 
RNASET2-mediated tumor suppression, we have recently demonstrated that, 
following selective in vivo depletion of the monocyte/macrophage cell lineage 
in immunodeficient mice, the RNASET2-mediated tumor suppression was 
impaired.  
In order to gain more insights into this non-cell autonomous RNASET2 
function, the first aim of my Ph.D. project was to investigate the putative 
occurrence of a functional cross-talk between extracellular RNASET2 protein 
and the tumor microenvironment. 
My working model is the following: RNASET2 protein could activate an host 
immunocompetent response against the tumor by means of (i) the production 
and secretion of signaling molecules, endorsed with immunological functions, 
by the RNASET2-overexpressing cancer cell itself, or (ii) a direct interaction 
between secreted RNASET2 protein and immunocompetent cells.  
As for the aforementioned first point, I have examined genes whose 
expression level is modulated by RNASET2 both in vitro and in vivo. More 
precisely, I have determined the gene expression profile of cultured RNASET2-
overexpressing ovarian tumor cell clones and compared it to that of xenograft 
tumors deriving from the injection of the same tumor clones into mice. 
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As for the second point, I have first investigated the cell-surface binding of 
RNASET2 protein on different tumor cell lines and on both native and M1/M2-
polarized human macrophages. Then, I have examined the mechanisms of a 
putative chemotactic activity of RNASET2 protein on both primary monocytes 
and pro-myelocytic cell lines.   
 
Being T2 ribonucleases so highly-conserved throughout all the phyla, from 
viruses to mammalian cells, we reckoned that RNASET2 could be endowed 
with an ancestral cell-autonomous activity, in particular within the context of a 
general stress-response. Indeed, an important role in counteracting nutrient 
starvation and pathogen attacks has been recently demonstrated for several 
members of the RNase T2 family in plants, fungi and yeasts. Since we have 
recently identified RNASET2 protein as a novel component of processing-
bodies, determining whether human RNASET2 plays a stress-response role in 
mammalian cells could thus be of great interest. 
To shed light on this issue, the second aim of my Ph.D. project was to 
investigate the putative cell autonomous role of human RNASET2 in general 
stress-response processes.  
To this end, I have challenged different tumor cell lines with a variety of stress-
inducing chemicals or treatments and then I have examined changes in both 
RNASET2 protein expression levels and sub-cellular localization patterns.  
 
 Results 
 
15 
 
RESULTS (Part I) 
As previously mentioned, the principal aim of my Ph.D. project has been to 
gain more insights into the non-cell autonomous tumor suppressive function of 
RNASET2 gene. Particularly, I have been involved in investigation of the 
putative occurrence of a functional cross-talk between extracellular RNASET2 
protein and the tumor microenvironment. 
 
The rationale of my experimental work was based on two main hypothesis, 
which are not mutually exclusive, about the mechanisms by which RNASET2 
carries out its oncosuppressive role in vivo: (i) RNASET2-overexpressing tumor 
cells could produce and secrete signaling molecules, endorsed with 
immunological functions, which in turn activate an host immunocompetent 
response against the tumor; (ii) RNASET2 protein secreted by the tumor cell 
could directly interact with immunocompetent target cells and recruit them at 
the tumor site (Figure 1). 
 
Figure 1 - Schematic representation for both the direct and the indirect model of cross-talk 
involving RNASET2-overexpressing tumor cells and innate immune cells. 
Within this conceptual framework, I'm presenting experimental data 
concerning both the aforementioned hypothesis.  
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RNASET2 overexpression in the tumor cell induces changes in gene 
expression profile, both in vitro and in vivo 
I decided to start my experimental investigations within the hypothesis of an 
indirect cross-talk involving RNASET2-overexpressing tumor cells and innate 
immune cells. More precisely, I assessed whether the RNASET2-overexpressing 
cancer cells showed changes in their gene expression pattern which could be 
consistent with the secretion of signaling molecules, such as cytokines and 
chemokines, involved in both recruitment and functional activation of innate 
immune cells.  
Although the best experimental setting for a tumor antagonizing gene is the in 
vivo context, I started my investigation with an in vitro setting, using the 
RNASET2-overexpressing Hey3Met2 ovarian cancer model in which we had 
previously demonstrated a strong in vivo tumor suppression (Acquati, 2005), 
together with a marked recruitment of immune cells at the tumor site 
(Acquati, 2011).  
Within this experimental context my principal aim was to detect upregulation 
of signaling molecules involved in innate immunity in RNASET2-overexpressing 
cells, with respect to control cells. Particularly, I have first defined the gene 
expression profile of RNASET2-overexpressing Hey3Met2 cell clones and 
compared it with that of control Hey3Met2 clones. To this end, an Agilent 
Whole Human Genome Oligo microarray was performed with total RNA from 
Hey3Met2 clones stably-overexpressing either the wild type or the catalitically 
inactive (H65/118F) form of the RNASET2 protein, both of them being effective 
in tumor suppression. Total RNA from Hey3Met2 clones stably transfected 
with the empty vector was used as a control. As a result, sixty-five genes were 
found to be modulated by RNASET2 and were further organized by hierarchical 
clustering (Figure 2) (Acquati, 2011).  
In order to define the cellular processes/pathways affected by RNASET2, all 
differentially-expressed genes were cross-referenced to the Gene Ontology 
database, which in turn did not show any significant enrichment, probably due 
to the small number of genes analyzed. Of note, quite unexpectedly, among 
the sixty-five modulated genes we have found no genes encoding signaling 
molecules involved in innate immunity.  
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Figure 2 - Image from: Acquati, F. (2011). Molecular signature induced by RNASET2, a tumor 
antagonizing gene, in ovarian cancer cells. Oncotarget 2, 477-484 
Nevertheless, among the sixty-five modulated genes we selected a set of 
thirteen RNASET2-responsive genes for further validation, mainly because of 
their involvement in cancer-related processes such as cell-adhesion, migration, 
proliferation and differentiation (Table 1) (Acquati, 2011). In fact, besides our 
data demonstrating a non-cell autonomous tumor suppressive function for the 
RNASET2 gene, we could not completely rule out the hypothesis that RNASET2 
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could also carry out a cell autonomous role that we had not previously 
investigated. 
 
Table 1 - Image from: Acquati, F. (2011). Molecular signature induced by RNASET2, a tumor 
antagonizing gene, in ovarian cancer cells. Oncotarget 2, 477-484 
In order to validate changes in the expression of these thirteen genes, I 
performed real time RT-PCR (qPCR) assays on the same RNA samples used for 
microarray hybridization. As a result, the pattern of gene expression changes 
observed following microarray hybridization was confirmed by qPCR for most 
tested genes (Figure 3A) (Acquati, 2011).  
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On the basis of these results, we asked whether some of these genes could 
have any relevance in RNASET2-mediated tumor suppression in vivo. To this 
end, since we could not perform an in vivo microarray analysis, total RNA 
extracted from xenograft tumors was employed for qPCR analysis of the 
expression pattern of the selected thirteen genes. As shown in Figure 3B, the 
RNASET2-mediated changes in the expression levels that we have previously 
observed in vitro were not confirmed for most tested genes in the in vivo 
setting. Indeed, significant changes in the expression pattern that were found 
to be in agreement with those observed in vitro could be reported for just 
three genes, namely LMCD1, DSE and RELB. 
 
Figure 3 - Image from: Acquati, F. (2011). Molecular signature induced by RNASET2, a tumor 
antagonizing gene, in ovarian cancer cells. Oncotarget 2, 477-484 
Taken together, these results provide a clear indication that investigations of 
the molecular mechanisms by which tumor antagonizing genes carry out their 
biological functions necessitate a thorough comparison between the in vitro 
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and the in vivo expression patterns. Thus, LMCD1, DSE and RELB genes 
represent bona fide candidate effector genes for RNASET2-mediated tumor 
suppression in vivo and are worth to be analysed in depth. However, these 
results clearly indicate that the employment of an in vitro approach to 
investigate biological properties of a gene which exerts its antitumoral function 
only in the in vivo context could not be the right choice. Thus, at least within 
the described experimental framework, the hypothesis of an indirect mode of 
action of RNASET2 protein in tumor suppression seems to be not so plausible. 
 
After the investigation of the indirect model of cross-talk between RNASET2-
overexpressing tumor cells and innate immune cells, I focused my 
experimental work on the hypothesis of a direct interaction between RNASET2 
protein and immunocompetent cells (Figure 4).  
 
Figure 4 - Schematic representation for the direct model of cross-talk involving RNASET2-
overexpressing tumor cells and innate immune cells. 
Central to this concept is the observation that the RNASET2 protein is secreted 
in the extracellular space and has therefore the potential to directly interact 
with a target cell. According to our previous data showing a consistent 
infiltration of host macrophage cells in RNASET2-overexpressing xenograft 
tumors, cells from the monocyte-macrophage lineage could reasonably 
represent potential target cells for this protein. Within this frame, I have first 
investigated the cell surface binding of RNASET2 protein in different target 
cells and then I assessed the chemotactic activity of RNASET2 protein on 
monocyte-macrophage cells. 
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RNASET2 protein binds to the tumor cell surface and could be internalized 
In order to gather evidence for a direct interaction between RNASET2 protein 
and the cell surface, I have first investigated the issue of a cell-surface binding 
of endogenously-produced RNASET2 protein on tumor cells. To this end, an in 
vivo cell-binding assay was firstly performed in the human cervical carcinoma-
derived HeLa cell line model, which showed an intermediate RNASET2 
expression level when compared to other cancer cell lines. The assay consisted 
in avidin-mediated precipitation of biotinylated cell surface proteins, followed 
by a Western blot analysis of the pulled-down proteins (Figure 5). As a result, 
endogenously produced RNASET2 actually proved to bind to the cell surface of 
human HeLa cancer cells. 
 
Figure 5 - Cell surface binding of RNASET2 protein on HeLa cells. HeLa cell surface proteins 
were labeled with biotin, then cells were lysed and the labeled proteins were pulled-down using 
an avidin-functionalized resin. A Western blot analysis was performed with both anti-RNASET2 
and anti-HSP90 primary antibodies on both pulled-down proteins (membrane bound MB) and 
column flow through (FT). HSP90 was only found in the FT, as expected for an exclusively 
intracellular protein. All of the three RNASET2 protein isoforms were found in the FT, while the 
secreted 36 kDa form was also found in the membrane-bound pulled-down proteins pool (black 
arrow).  
Therefore, I decided to test the cell surface binding of endogenously-produced 
RNASET2 protein in other human tumor cell lines, including our experimental 
model: ovarian carcinoma cells. To this end, a flow cytometry analysis was 
performed using a fluorophore-conjugated anti-RNASET2 antibody. As a result, 
a significant membrane RNASET2-relative fluorescent signal was detected in a 
human ovarian cancer cell line (OVCAR3), in two human colon cancer cell lines 
(RKO and HTC-116) and in a human fibrosarcoma-derived cell line (8387) 
(Figure 6). 
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Figure 6 - Cell surface binding of RNASET2 protein on tumor cells. Briefly, cells were harvested 
and incubated for 30 minutes in the dark with fluorophore-conjugated anti-RNASET2 primary 
antibody. Each bar represents RNASET2 relative MFI (membrane fluorescence intensity) value, 
that is the ratio between RNASET2 MFI and isotypic control (anti-human rabbit IgG) MFI. A ratio 
equal to 1 (black baseline) means no RNASET2-specific membrane signal. 
Finally, I have employed a different experimental approach to confirm 
RNASET2 binding to the plasma membrane and to investigate the possibility of 
the internalization of the surface-bound protein. We have recently established 
in our laboratory an RNA interference-mediated silencing of RNASET2 in the 
human ovarian cancer cell line OVCAR3, which is a poorly tumorigenic cancer 
cell line with high RNASET2 endogenous levels (Acquati 2012, submitted) 
(Figure 7).  
 
Figure 7 - RNASET2 knockdown in the human ovarian cancer cell line OVCAR3. a) Western blot 
analysis of RNASET2 protein expression in parental OVCAR3 cells and in either si-scrambled or si-
RNASET2 stably-transfected OVCAR3 clones. RNASET2 protein resulted completely absent in 
silenced OVCAR3 cells. b) Indirect IF assay showing cytoplasmic RNASET2 staining in OVCAR3 
cells and confirming RNASET2 knockdowm in silenced OVCAR3 clones. Particularly, a peri-
nuclear localization is highlighted (white arrows). Confocal microscopy images. 40X. 
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Using this model, I have performed an indirect immunofluorescence assay with 
an anti-RNASET2 antibody on stably RNASET2-silenced OVCAR3 cells after a 24 
hours exposure to a conditioned medium rich in RNASET2. Particularly, cells 
were either permeabilized or left untreated after fixation, in order to confirm 
not only the cell surface binding, but also investigate the possibility of the 
internalization of the membrane-bound protein.  
As a result, only a surface RNASET2 signal was obtained in the unpermeabilized 
cells. In the permeabilized RNASET2-silenced OVCAR3 cells, by contrast, a 
cytoplasmic signal was also detectable, consistent with the hypothesis of 
RNASET2 binding to the cell-surface which is then followed by the 
internalization of the protein within the cancer cell itself (Figure 8a). Of note, 
the same results were obtained after a 24 hours exposure of RNASET2-silenced 
OVCAR3 cell clones to recombinant RNASET2 protein produced in the 
baculovirus/insect cells heterologous expression system (Figure 8b). 
 
Figure 8 - Surface binding and internalization of exogenously-provided RNASET2 protein in 
RNASET2-silenced OVCAR3 cells. RNASET2-silenced OVCAR3 cells plated on coverslips were 
incubated for 24 hs with either a conditioned medium rich in RNASET2 (a) or the recombinant 
RNASET2 protein at the final concentration of 1 µM (b). After incubation, cells were either fixed 
and permeabilized or only fixed and immunostained. In untreated RNASET2-silenced cells, no 
RNASET2 signal was detectable (a1). A cell surface staining was detectable in unpermeabilized 
cells (a2, b2). A cytoplasmic staining was also observable after permeabilization, thus suggesting 
the internalization of the membrane-bound protein (a3, b3).   
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Taken together, these data demonstrate that endogenously-produced 
RNASET2 protein could bind the tumor cell surface. Moreover, using our 
RNASET2-silenced ovarian cancer cell model, I also demonstrated that 
exogenously-provided RNASET2 protein could be internalized following the 
binding to the tumor cell surface.  
Noteworthy, as previously mentioned, the target cell of RNASET2 function is 
likely to be the innate immune cell, rather than the cancer cell. However, these 
results demonstrating both the cell surface binding and the internalization of 
RNASET2 protein within the cancer cells suggest the existence of a common, 
likely receptor-mediated, binding/internalization pathway for RNASET2 
protein, which could be cell-type independent. 
 
RNASET2 protein binds to human macrophage cell surface in a dose-
dependent manner 
After investigating the cell surface binding of RNASET2 protein on tumor cells, I 
focused my work on the cell-type which could more likely represent the target 
of RNASET2. According to this view, extracellular RNASET2 could be directly 
involved in recruiting innate immune cells at the tumor site and these 
immunocompetent cells could eventually mediate the effective tumor 
suppression that we have observed in mice after injection of RNASET2-
overexpressing tumor clones.  
To shed light on this issue, I have first investigated the cell surface binding of 
exogenously-provided RNASET2 protein on both native and M1/M2 polarized 
human macrophages. To this end, after exposure to increasing concentrations 
of recombinant human RNASET2 protein purified from Pichia pastoris, a flow 
cytometry analysis was performed to detect the cell surface binding using a 
fluorophore-conjugated anti-RNASET2 antibody. As a result, a significant and 
dose-dependent binding to the cell surface was detected on both native and in 
vitro M1/M2 polarized human macrophages, thus suggesting a receptor-
mediated interaction between RNASET2 protein and innate immune cells 
(Figure 9). 
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Figure 9 - Cell surface binding of recombinant human RNASET2 on human macrophages. 
Briefly, monocytes isolated from buffy coats were differentiated in macrophage cells and M1 or 
M2 polarization was induced with specific cytokines. Therefore, cells were seeded in 96-wells 
plates and incubated with recombinant human wild-type RNASET2 protein at 4°C for 3 hours. 
Then, cells were harvested and incubated for 30 minutes in the dark with fluorophore-
conjugated anti-RNASET2 primary antibody. Each bar represents RNASET2 relative MFI 
(membrane fluorescence intensity). MØ: native human macrophages. M1: M1-polarized human 
macrophages. M2: M2-polarized human macrophages. 
The observed RNASET2 protein binding to macrophage cells could suggested 
that, when secreted in the extracellular space from the cancer cell, RNASET2 
could have a chemotactic role in recruiting immunocompetent cells at the 
tumor site. 
 
RNASET2 protein is endowed with chemotactic activity on both human 
primary monocytes and the U937 cl.10 promyelocytic cell line 
In order to gain more insights into the mechanisms of interaction between 
RNASET2 protein and innate immune cells, I decided to assess the chemotactic 
activity of the protein on human primary monocytes isolated from peripheral 
blood of healthy donors.  
To this end, I have first purified recombinant RNASET2 protein, both wild-type 
and catalytically-inactive (H65/118F), expressed in two different heterologous 
systems: baculovirus/insect cells (BEVS) and Pichia pastoris. Recombinant 
RNASET2 protein purification was performed in two steps: (i) an affinity 
chromatography on Ni-NTA agarose columns, which exploited the C-terminal 
6xHis tag of the protein, and (ii) a SEC/FPLC polishing step (Figure 10). 
Subsequently, I have assessed the protein preparations in order to exclude the 
presence of contaminant endotoxins, which are known to interfere in 
migration assays on monocytes, using a qualitative LAL-test.  
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Figure 10 - Recombinant human RNASET2 protein purification. Both wild-type and H65/118F 
recombinant RNASET2 proteins produced in two heterologous expression systems were affinity-
chromatography purified and then subjected to a SEC/FPLC polishing step. Chromatograms show 
the elution peaks for the protein. Recombinant RNASET2 protein produced in Pichia pastoris is 
hyperglycosylated with respect to that produced in BEVS. Below the corresponding peaks is the 
Western blot analysis of each eluted fraction. Three different primary antibodies were used to 
assess both the presence and the integrity of the purified protein: anti-RNASET2, anti-HA tag and 
anti-His tag. 
The endotoxin-free recombinant RNASET2 protein was then tested as a 
chemotactic factor on human monocytes isolated from buffy coats. To this 
end, I first performed pilot migration tests in blind-well chambers, in which 
monocytes were exposed to increasing concentrations of recombinant wild-
type human RNASET2 protein. As a result, I obtained migration responses to 
RNASET2 protein reminiscent of a bell-shaped curve, which is the expected 
trend for a chemokine (Figure 11). According to these results, the RNASET2 
protein concentration of 0.227 µM, corresponding to 8.172 mg/l, was chosen 
for the following experiments. 
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Figure 11 - Recombinant human wild-type RNASET2 protein exerts a chemotactic activity on 
human monocytes from buffy coats. Peripheral blood mononuclear cells (PBMC) were gradient-
separated from buffy coats and monocytes were isolated by plating. Chemotaxis assays were 
performed in blind well chambers. Briefly, chemoattractants diluted in serum-free RPMI medium 
were placed in the lower well of the chamber, while cells were seeded in the upper well. The 
two wells are separated by a porous filter, which allows cells to migrate in response to the 
chemoattractant. After a three-hours incubation, non-migrating cells were scraped, filters were 
fixed and cells were stained with hematoxylin/eosin and counted using a light microscope. a) 
Bars represent the relative migration mean values from three independent experiments. Serum-
free RPMI medium was used as negative control, while the CCL2 chemokine was used as positive 
control for monocytes migration. The recombinant protein elution/storage buffer was used as 
negative control for migration in response to recombinant RNASET2 protein (Neg. BEVS and Neg. 
Pichia). Statistical analysis of data was performed with bilateral Student's t-test. A bell-shaped 
migration curve was obtained for both the BEVS and the Pichia pastoris recombinant human 
wild-type RNASET2 protein. b) Four representative light microscopy images. Filter pores (small 
dark brown rounds) and migrating monocytes (violet) are observable. 40X.  
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Of note, in performing migration assays on monocytes isolated from buffy 
coats I have recorded a large variability from one test to another. This is most 
likely due to the fact that monocytes from different patients are markedly 
heterogeneous, thus making difficult to obtain reproducible results. In order to 
overcome this problem and standardize the method, I decided to perform 
migration assays with RNASET2 protein in a human promyelocytic cell line, 
rather than in freshly-isolated human monocytes. To this end, I have first 
evaluated the RNASET2 endogenous expression levels in four different 
promyelocytic cell lines (Figure 12). Then, in order to allow the establishment 
of an RNASET2 gradient within the migration chamber, the cell line which 
showed the lowest RNASET2 protein expression levels (U937 cl.10) was 
selected for the following experiments. 
 
Figure 12 - RNASET2 protein endogenous levels in four human promyelocytic cell lines. A 
Western blot analysis was performed on both total protein extracts (IC RNASET2) and 
supernatants (EC RNASET2). α-tubulin was used for normalization. U937 cl.10, a human 
promyelocytic cell line derived from histiocytic lymphoma, showed the lowest RNASET2 protein 
levels. 
Thus, I have performed migration assays on U937 cl.10 cell line using both 
wild-type and H65/118F recombinant human RNASET2 protein produced both 
in BEVS and in Pichia pastoris heterologous expression systems. As a result, I 
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observed a consistent migration in response to both the wild-type and the 
catalytically-inactive form of RNASET2 protein (Figure 13).  
 
Figure 13 - Recombinant human RNASET2 protein, both wild-type and catalytically-inactive, 
exerts a strong chemotactic activity on U937 cl.10 promyelocytic cell line. Chemotaxis assays 
were performed in blind well chambers. Bars represent the relative migration mean values from 
two independent experiments. Serum-free RPMI medium was used as negative control, while 
the CCL2 chemokine was used as positive control for cell migration. The recombinant protein 
elution/storage buffer was used as negative control for migration in response to recombinant 
RNASET2 protein (Neg. BEVS and Neg. Pichia). Statistical analysis of data was performed with 
bilateral Student's t-test. 
Taken together, these results strongly suggest that extracellular RNASET2 
protein could actively behave as a chemokine in recruiting cells from the 
monocyte-macrophage cell lineage at the tumor site.  
 
Since the RNASET2 protein proved to directly interact with monocyte-
macrophage cells and also showed a chemotactic activity on this cell 
population, I decided to investigate the occurrence of receptor-mediated 
binding of the RNASET2 protein to the target cell surface. Intracellular signaling 
pathways in response to chemokines are in most cases triggered by the binding 
of the signaling molecule to a cell-surface G-protein coupled receptor (GPCR) 
(Murphy, 1994). I thus replicated the migration assays on U937 cl.10 cells 
following pre-treatment of cells with pertussis toxin (PTx), which is known to 
inhibit the GPCRs function by means of ADP-ribosylation of Gi proteins. As a 
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result, PTx pre-treatment drastically impaired U937 cl.10 cells migration in 
response to recombinant wild-type human RNASET2 protein (Figure 14). 
 
Figure 14 - Human RNASET2 protein exerts a chemotactic activity on U937 cl.10 cell line by 
means of a GPCRs-mediated cell-surface binding. a) U937 cl.10 cells were either pre-treated 
with 1 µg/ml PTx for three hours or left untreated. In vitro migration assays were performed in 
blind well chambers. Recombinant wild-type human RNASET2 protein produced in BEVS and 
CCL2 chemokine were used as chemoattractants, at the final concentrations of 8.172 µg/ml and 
100 ng/ml, respectively. Statistical analysis was performed with bilateral Student’s t-test. 
**p<0.01. b) Fluorescence microscopy images of filters. After fixation, nuclei were stained with 
DAPI. 40X.  
On the basis of this body of evidence, I propose that RNASET2 could exert its 
tumor-antagonizing role by means of a direct receptor-mediated interaction 
with the monocyte-macrophage cell population, whose functional activation 
could be finally responsible for the RNASET2-mediated tumor suppression that 
we have observed in the in vivo settings.  
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RESULTS (Part II) 
 
RNASET2 protein levels increase following stress induction 
As I have previously argued, T2 ribonucleases are highly-conserved enzymes 
throughout all the phyla, from viruses to mammalian cells. In particular, these 
RNases are well known to increase their expression levels in plants, fungi and 
yeasts in response to stress challenges such as nutrient starvation, chemically-
induced cellular stresses and pathogen attacks (Deshpande, 2002). Being the 
T2 ribonucleases stress-response role so highly conserved, we reckoned that a 
similar function could be hypothesized for mammalian cells as well.  
In order to start to investigate this issue, we took advantage of some 
information we have recently collected concerning the subcellular co-
localization of RNASET2 protein with processing-bodies markers (Vidalino, 
2012). As already mentioned, PBs are transient cytoplasmic structures mainly 
associated with the mRNA decay process (Kedersha & Anderson, 2007).  
 
Thus, we decided to set up a panel of experiments aimed at uncovering 
whether human RNASET2 plays a stress-response role in mammalian cells. To 
this end, I have challenged different tumor cell lines with a variety of stress-
inducing chemicals or treatments and then I have examined changes in both 
RNASET2 protein expression levels and sub-cellular patterns of localization.  
I have performed in vitro stress induction assays using a standardized cancer 
cell line model (HeLa) and two ovarian cancer cell lines, Hey3Met2 and SKOV3, 
as an experimental model. I decided to challenge these cell lines with 
metabolic stress, oxidative stress, osmostress, heat shock, UV light, aminoacid 
starvation and chemical hypoxia. After each treatment and following the 
proper recovery time, I have assessed RNASET2 protein levels by Western Blot 
analysis in stress-exposed cells with respect to untreated cells.  
As a result, I observed significantly higher RNASET2 protein levels in treated 
Hey3Met2 and SKOV3 cells, in response to different stresses. Particularly, we 
detected specific patterns of RNASET2 protein isoforms overexpression in 
response to different stress inductions; indeed, the 31 kDa and the 27 kDa 
isoforms were significantly more represented in treated cells with respect to 
control cells following clotrimazole treatment, heat shock, aminoacid 
starvation and hypoxic stress (Figure 15 and Table 2).  
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Figure 15 - Specific human RNASET2 protein isoforms overexpression in response to stress 
induction. A Western Blot analysis was performed on total protein extracts obtained from both 
treated and control cells following stress induction. Signals quantification was performed with 
ImageJ software. α-tubulin was used for signal normalization. a) An overall higher RNASET2 
protein level was observed in clotrimazole-treated Hey3Met2 cells (red bar). The 27 kDa 
RNASET2 isoform was induced in response to metabolic stress, UV-light exposure and aminoacid 
starvation (yellow bars). The 31 kDa RNASET2 isoform was induced in response to aminoacid 
starvation (green bar). b) The full-length 36 kDa RNASET2 protein was induced in SKOV3 cells in 
response to heat shock (pink bar). The 27 kDa RNASET2 isoform was induced in response to 
clotrimazole treatment and aminoacid starvation (yellow bars). c) In CoCl2-treated SKOV3 cells 
we observed significant induction of the 36 kDa RNASET2 protein isoform, at both the 
intracellular (pink bars) and the extracellular (EC RNASET2) levels. HIF-1α was used as an hypoxia 
marker.  
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Table 2 - Human RNASET2 protein levels change following stress induction. Treated VS 
untreated cells relative fold-changes are reported for each cell line. Western Blot signals 
quantification was performed with ImageJ software. Mean values from two/three independent 
experiments are reported. RNASET2 protein level in untreated cells was arbitrarily based to 1. 
Metabolic stress: 500 µM NaAsO2 for 45 minutes, followed by a 120-minutes recovery period. 
Oxidative stress: 20 µM clotrimazole for 60 minutes, in serum-free medium. Osmotic shock: 1 M 
D-sorbitol for 30 minutes in either serum-free or complete medium. Heat shock: 42°C for 20 
minutes, followed by a 24-hours recovery period. UV-light exposure: 312 nm (UVB) for 1 minute, 
followed by a 30-minutes recovery period. Aminoacid starvation: 48-hours incubation with 
DMEM with 4.5 g/l glucose and NaHCO3, without Methionine, Cysteine and Glutamine. Hypoxic 
stress: 200-400 µM CoCl2 for either 12 or 24 hours. Positive fold-changes are in light and dark 
green; negative fold-changes are in light and dark red. 
* 
Fc value referred to 36 kDa isoform. 
** 
Fc 
value referred to extracellular 36 kDa isoform. 
# 
Fc value referred to 31 kDa isoform. 
§ 
Fc value 
referred to 27 kDa isoform. 
Moreover, where I have observed overexpression of the intracellular 36 kDa 
form of the RNASET2 protein, I have also recorded a concomitant increase in 
the secreted protein level (Table 2). RNASET2 expression turned out to change 
in response to several stresses in HeLa cells as well, although the observed 
pattern was significantly different from that I have observed in the above 
mentioned ovarian cancer cell lines (Table 2).  
These preliminary results are clearly compatible with a role for human 
RNASET2 as a wide-range stress response gene.  
 
RNASET2 protein re-localizes to P-bodies in response to hypoxic stress 
conditions 
I have demonstrated that RNASET2 protein levels increase in response to 
different stress-inducing treatments. According to this descriptive observation, 
I decided to deeply investigate the functional significance of the observed 
RNASET2 increase in response to stress, particularly in the context of P-bodies 
dynamics. Indeed, as previously mentioned, we have recently demonstrated a 
co-localization between RNASET2 protein and PBs markers (Vidalino, 2012). In 
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order to better clarify this issue, I'm presenting here some preliminary 
experiments and results. 
I have challenged SKOV3 cells with CoCl2 treatment, which induces chemical 
hypoxia, and then I have processed cells for double indirect 
immunofluorescence in order to assess the re-localization of RNASET2 protein 
to PBs. To this end, a primary anti-RNASET2 antibody was employed, together 
with a primary anti-DCP1 antibody, which is a well-known PBs marker protein. 
As a result, I have detected a marked co-localization signal for RNASET2 and 
DCP1 proteins in treated SKOV3 cells when compared to the untreated cells 
(Figure 16).  
 
RNASET2 knockdown leads to increase in P-bodies and stress-granules 
number 
Afterwards, I decided to better investigate the functional role of RNASET2 
protein in RNA metabolism and particularly in P-bodies (PBs) and stress-
granules (SGs) dynamics. Briefly, SGs are cytoplasmic phase-dense structures 
that occur in cells exposed to environmental stress and are composed of 
stalled translation pre-initiation complexes (Kedersha & Anderson, 2007).  
In order to shed light on this issue, I have employed the RNASET2 knock-down 
experimental model that we have obtained in the human ovarian cancer cell 
line OVCAR3. Particularly, I have first assessed whether RNASET2 knockdown 
could per se influence PBs number and size, without administering any specific 
stress induction. Using indirect immunofluorescence with a PBs-specific 
marker (RCK/p54), I was able to detect a significant increase in P-bodies 
number and size in RNASET2-silenced OVCAR3 clones when compared to 
control clones (Figure 17a). Therefore, using the same experimental approach, 
I have investigated changes in SGs sub-cellular signal and I have obtained 
results in the same direction as for PBs (Figure 17b).  
A possible explanation for the observed findings could be that cells lacking 
RNASET2 have a basal cellular stress level higher than cells in which RNASET2 
protein is normally expressed. According to this view, I decided to assess 
whether OVCAR3 cells lacking RNASET2 showed RNA accumulation at the 
cytoplasmic level. To this purpose, an RNA-specific fluorescent dye was 
employed but no differences have been noticed in cytoplasmic staining of 
RNASET2-silenced OVCAR3 clones when compared to control clones (Figure 
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17c). Finally, according to our previous data demonstrating a lysosomal 
subcellular location for RNASET2 enzyme (Campomenosi, 2006), I decided to 
investigate whether cells lacking RNASET2 showed changes at the lysosomal 
compartment level. No changes in the staining pattern of lysosomes were 
observed in RNASET2-silenced OVCAR3 cells with respect to control clones 
(Figure 17d). 
 
Taken together, these data suggest that human RNASET2 could play an 
housekeeping role in orchestrating defense mechanisms against stress 
conditions at the cellular level. 
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Figure 16 - RNASET2 protein re-localizes to P-bodies in response to hypoxia. SKOV3 cells were 
seeded on coverslips and treated with 400 µM CoCl2 for 24 hours. After treatment, cells were 
fixed, permeabilized and processed for indirect immunofluorescence. The p38 MAP-kinase, 
which is known to translocate to the nucleus in response to hypoxic stress, was used as an 
experimental control (a). A double indirect immunofluorescence was performed to assess 
RNASET2 re-localization to P-bodies. DCP1 protein was used as PBs marker. No significant co-
localization signal was detected in untreated SKOV3 cells (b, upper panel) while a marked co-
localization (white arrows) was detected following hypoxia-inducing treatment (b, lower panels). 
Fluorescence microscopy images. 40X. 
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Figure 17 - OVCAR3 cells lacking RNASET2 show increase in PBs and SGs number. Two 
independent RNASET2-silenced OVCAR3 cell clones were employed and compared to two 
independent control OVCAR3 cell clones. Briefly, cells were seeded on coverslips, indirect 
immunofluorescence was performed and fluorescence microscopy images (a, b, c) or confocal 
microscopy images (d) were acquired. Signal quantification was performed with the "Analyze 
particles" function of the ImageJ software and normalized on counted cell number (DAPI signal, 
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where present). Bars represent the relative fold-changes calculated. Approximately 500 cells for 
each of the four clones were counted. Statistical analysis of data was performed with bilateral 
Student's t-test. RCK, YBX1 and LAMP-2 are marker proteins for PBs, SGs and lysosomes, 
respectively. SYTO RNA select is an RNA-specific fluorescent dye. A significant increase in PBs (a) 
and SGs (b) was observed in RNASET2-silenced OVCAR3 clones with respect to control clones. No 
changes in both total RNA amount (c) and lysosomal staining pattern (d) were observed.  
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MATERIALS AND METHODS 
 
CELL CULTURES 
Primary cells 
Human monocytes were isolated from peripheral blood using Lympholyte®-H 
(CEDARLANE), a density gradient separation medium specifically designed for 
the isolation of viable lymphocytes and monocytes.  
Native human macrophages were differentiated from monocytes with a six-
days exposure to 100 ng/ml MCSF. M1-polarization was induced with 100 
ng/ml LPS + 20 ng/ml IFN-γ. M2-polarization was induced with 20 ng/ml IL-4. 
Culture medium: RPMI-1640 + 10% heat-inactivated FBS + 1% L-glutamine. 
Culture conditions: 37°C, 5% CO2, humidified atmosphere. 
Cell lines 
Adhesion growth: Hey3Met2 (human ovarian cancer); HeLa (human cervical 
carcinoma); OVCAR3 (human ovarian cancer); RKO (human colon cancer); HTC-
116 (human colon cancer); 8387 (human fibrosarcoma); SKOV3 (human 
ovarian cancer). Culture medium: DMEM/DMEM-F12 + 10% FBS + 1% L-
glutamine.  
Suspension growth: U937 (human histiocytic lymphoma); U937 cl.10 (human 
histiocytic lymphoma, HIV-permissive clone); U937 cl.34 (human histiocytic 
lymphoma, HIV non-permissive); THP-1 (human acute monocytic leukemia). 
Culture medium: RPMI-1640 + 10% heat-inactivated FBS + 1% L-glutamine. 
Culture conditions: 37°C, 5% CO2, humidified atmosphere.  
Stably-transfected cell clones 
Hey3Met2 empty pcDNA3; Hey3Met2 pcDNA3-hRNASET2 w.t.; Hey3Met2 
pcDNA3-hRNASET2 H65/118F. Culture medium: DMEM-F12 + 10% FBS + 1% L-
glutamine + 350 µg/ml G418. 
OVCAR3 empty pSICO; OVCAR3 pSICO-siSCRAMBLED; OVCAR3 pSICO-
siRNASET2. Culture medium: DMEM-F12 + 10% FBS + 1% L-glutamine + 1.5 
µg/ml puromycin.  
Culture conditions: 37°C, 5% CO2, humidified atmosphere. 
ANTIBODIES AND FLUORESCENT DYES  
Primary Abs: polyclonal rabbit anti-hRNASET2 (Dabio, Germany); monoclonal 
mouse anti-hHSP90 (SIGMA-ALDRICH); monoclonal mouse anti-HA tag (Roche, 
Milan, Italy); monoclonal mouse anti-His tag (Santa Cruz Biotechnology); 
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monoclonal mouse anti-αtubulin (SIGMA-ALDRICH, T-9026); monoclonal 
mouse anti-DCP1 (Abnova, H00055802-M06); monoclonal mouse anti-RCK/p54 
(Santa Cruz Biotechnology); polyclonal rabbit anti-p38 (Cell Signaling 
Technology); monoclonal mouse anti-YBX1 (Abnova); monoclonal mouse anti-
LAMP2 (Santa Cruz Biotechnology). Secondary Abs: goat anti-mouse IgG HRP-
conjugated (PIERCE); goat anti-rabbit IgG HRP-conjugated (PIERCE); goat anti-
mouse IgG TRITC-conjugated (SIGMA-ALDRICH); goat anti-rabbit IgG FITC-
conjugated (SIGMA-ALDRICH). Fluorescent dyes: 4ɂ,6-Diamidino-2-phenylindole 
dihydrochloride (SIGMA-ALDRICH); SYTO®RNASelect™ Green Fluorescent Cell 
Stain (Molecular Probes, S32703). 
STRESS-INDUCING CHEMICALS AND REAGENTS 
Sodium (meta)arsenite NaAsO2 (SIGMA-ALDRICH, S-7400); Clotrimazole 
(SIGMA-ALDRICH, C-6019); D-sorbitol (SIGMA-ALDRICH, 240850); Dulbecco's 
Modified Eagle's Medium-high glucose-without L-methionine, L-cysteine and L-
glutamine (SIGMA-ALDRICH, D-0422); Cobalt(II) chloride CoCl2 (SIGMA-
ALDRICH, 60818). 
MICROARRAY GENE EXPRESSION ANALYSIS 
The Agilent Whole Human Genome Oligo Microarray was performed in 
collaboration with the Institute for Health and Consumer Protection, Molecular 
Biology and Genomics Unit of the Joint Research Centre (Ispra, Varese, Italy). 
The in vitro microarray analysis was performed on total RNA extracted from 
Hey3Met2 cell clones (TRI reagent, SIGMA-ALDRICH). The GO analysis was 
done at GO FAT level of biological process and molecular function, whereas 
Expression Analysis Systematic Explorer (EASE) biological theme analysis was 
carried out online using DAVID (http://david.niaid.nih.gov).  
QUANTITATIVE REAL TIME RT-PCR 
Total RNA was extracted from Hey3Met2 cells and xenograft tumors with TRI 
reagent (SIGMA-ALDRICH), was subjected to DNase treatment and was reverse 
transcribed with random examers using the High-capacity cDNA RT kit (Applied 
Biosystems). Primer sequences were designed with the Primer express 
program (Applied Biosystems). Real-time RT-PCR was performed on ABI PRISM 
7000 with the Power SYBR-green PCR Master Mix (Applied Biosystems), 
following the manufacturer's instructions. Amplification reactions were 
performed in triplicate. Following a polymerase activation step at 95°C for 10 
minutes, samples were denatured at 95°C for 15'' and annealed/extended at 
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60°C for 1 minute, for 40 cycles. Fluorescent signals generated during PCR 
amplification were monitored and analyzed with ABI PRISM 7000 SDS software 
(Applied Biosystems). Comparison of the amount of each gene transcript 
among different samples was made using β-actin as reference. The amount of 
target RNA, normalized to the endogenous reference gene, was calculated by 
means of the difference-in-threshold-cycle parameter ΔCt.  
CELL SURFACE PROTEINS ISOLATION 
In order to obtain biotinylation and isolation of cell surface proteins for 
Western blot analysis, the Pierce®Cell Surface Protein Isolation Kit (THERMO 
SCIENTIFIC) was employed, according to the manufacturer's instructions. 
Briefly, cells were first labeled with EZ-Link Sulfo-NHS-SS-Biotin, a thiol-
cleavable amine-reactive biotinylation reagent. Subsequently, cells were lysed 
with a mild detergent and the labeled proteins were then isolated with 
NeutrAvidin Agarose. The bound proteins were released by incubating with 
SDS-PAGE sample buffer containing 50 mM DTT and processed for Western 
Blot analysis.  
WESTERN BLOT ANALYSIS 
Cells for intracellular extracts were mechanically scraped in PBS + 5mM EDTA 
and resuspended in lysis buffer (0.5% Igepal, 0.5% Triton X-100 in PBS + 5mM 
EDTA) supplemented with protease inhibitors (PMSF, benzamidine, aprotinin, 
and leupeptin). Quantification of total proteins was performed with Bradford 
reagent (BIO RAD), using bovine serum albumin as standard. For the SDS-PAGE 
analysis, 30-70 µgs of intracellular lysate were loaded. Immunoblot analysis 
was performed using standard procedures and detected with a 
chemiluminescent substrate (Super-signal West Dura extended duration kit, 
Thermo Scientific). When necessary, acquired images were quantified using 
the "Analyze gels" tool of the ImageJ software.  
FLOW CYTOMETRY ANALYSIS 
The flow cytometry analysis was performed in collaboration with the 
Laboratory of Immunopharmacology of the Humanitas clinical institute, IRCCS 
(Rozzano, Milan, Italy). The Zenon Rabbit IgG Labeling Kit (Molecular Probes) 
was employed in order to produce an antibody conjugate anti-
RNASET2/fluorophore, following the manufacturer's instructions. Briefly, the 
following protocol was performed for the staining of the cells. Cell suspension 
(1 × 106 cells/mL) was mixed with the Zenon labeling mixture and incubated for 
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30 minutes at room temperature. Then, cells were washed once with PBS, 
centrifuged, resuspended and analyzed using appropriate instrument 
parameters. 
In order to perform flow cytometry analysis for binding of the exogenously-
provided RNASET2 protein, the same protocol was used after a three-hours 
incubation at 4°C with the recombinant RNASET2 protein or the appropriate 
isotypic control. 
INDIRECT IMMUNOFLUORESCENCE ASSAYS 
Cells were grown on coverslips for 24 hours and then treated or directly 
processed for indirect immunofluorescence. Cells were fixed either in 3% 
paraformaldehyde or Methanol, depending on the primary antibody 
employed. After fixation, cells were permeabilized using Triton X-100 and 
incubated in a 10% goat serum blocking solution in PBS 1X. Primary and 
secondary antibodies incubations were performed in diluted blocking solution 
(3% goat serum in PBS). Cell nuclei were counterstained with DAPI and 
coverslips were mounted on microscope slides using Vectashield mounting 
medium (Vector). Fluorescence/confocal microscopy images were acquired. 
Image quantification analysis was performed using the "analyze particles" tool 
of the ImageJ software. Statistical analysis was performed using an 
independent two sample Student's t-test (unequal sample size, equal 
variance). 
RECOMBINANT PROTEIN PURIFICATION FROM SUPERNATANTS 
Recombinant wild-type and mutant proteins were both secreted in the 
extracellular medium using the endogenous RNASET2 secretion signal and 
could therefore be easily purified from supernatants of both BEVS and Pichia 
pastoris systems. Supernatants were 10/15-fold concentrated using Centricon 
Plus 70 (MILLIPORE) and dialyzed against 50 mM Tris–HCl, 100 mM KCl, at pH 
8.0 (Base solution) in order to improve subsequent binding to the Ni-NTA 
agarose resin (Qiagen). Binding to the resin was allowed to proceed in falcon 
tubes, after addition of 10 mM imidazole, at 4°C for 2 hs before applying onto 
an empty poly-prep chromatography column (Bio Rad). After washes with 20 
column volumes of wash solution (Base solution + 50 mM imidazole), elution 
was performed with four column volumes (one volume at a time) of base 
solution + 250 mM imidazole. Presence of the protein in eluted fractions was 
checked by SDS–PAGE analysis followed by Coomassie staining. Protein 
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containing fractions were pooled and dialyzed against 10 mM potassium 
phosphate, 0.2 mM β-mercaptoethanol, pH 6.6 and then stored at 20°C in 
small aliquots. A second step of protein purification was performed by 
SEC/FPLC, in collaboration with the Laboratory of functional post-genomic and 
protein engineering of the University of Insubria (Varese, Italy). The LAL-
PYROGENT single test vials kit (LONZA) was employed in order to exclude any 
endotoxin contamination of the final protein preparations.  
CHEMOTAXIS ASSAYS 
The Lympholyte®-H reagent (CEDARLANE) was used for the isolation of human 
monocytes from buffy coats. This is a density gradient separation medium 
specifically designed for the isolation of viable lymphocytes and monocytes 
from human peripheral and cord blood. It allows the elimination of 
erythrocytes and dead cells from human blood and also removes the majority 
of granulocytes. The resulting cell population consists of a high and non-
selective recovery of viable human lymphocytes and monocytes. Monocytes 
were further isolated from lymphocytes by plating. 
In vitro migration assays on both primary monocytes and promyelocytic cell 
lines were performed in blind well chambers (NeuroProbe). A polycarbonate 
filter with 3 µm pores (NeuroProbe) separated the upper and the lower 
chamber, in order to allow migrating cells to get through the pores. Cells were 
incubated in serum-free RPMI-1640 medium for 24 hours before starting the 
test. Then, cells were resuspended in serum-free medium at a final density of 
6x105 cells/ml and were placed in the upper compartment of the chambers 
(500 µl/well). Chemoattractant agents were diluted in serum-free medium and 
were put in the lower compartment of the chambers (200 µl/well). Chambers 
were incubated for 3 to 21 hours at 37°C, in order to allow migration to occur. 
After incubation, non-migrated cells were scraped and filters were fixed, 
stained with haematoxilin-eosin (Diff-Quik staining protocol-Medion 
Diagnostics) and mounted on microscopy slides (7,5 µg/ml DAPI in Vectashield 
mounting medium). Nuclei were counted and relative migration values were 
calculated. As negative control, the protein storage buffer diluted in serum-
free RPMI-1640 medium was used. Statistical analysis was performed using 
bilateral Student's t-test for unpaired data.     
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PERTUSSIS TOXIN (PTx) TREATMENT 
U937 cl.10 cells were harvested and resuspended at a final density of 1 x 106 
cells/ml in serum-free RPMI-1640 medium. Treatment with 1 µg/ml PTx 
(CalBiochem) for 90 minutes was performed at 37°C, 5% CO2. After incubation, 
cells were washed twice in PBS and then resuspended for chemotaxis assay.  
STRESS-INDUCING TREATMENTS 
Stress-inducing treatments were performed following protocols suggested by 
Kedersha and Anderson (Kedersha & Anderson, Mammalian stress granules 
and processing bodies, 2007). The following table summarizes the employed 
procedures. 
Treatment/Reagent Conditions 
Recovery 
time 
Effects Comments 
Metabolic stress 
Sodium (meta)arsenite, 
NaAsO2 
500 µM, 45' 120' 
Induces 
both SGs 
and PBs 
/ 
Oxidative stress 
Clotrimazole 
20 µM, 60' / 
Induces 
SGs 
Requires serum-
free media 
Osmostress 
D-sorbitol 
1 M, 30' / 
Induces 
SGs 
Duration of 
exposure is more 
important than 
degree of 
hypertonicity 
Heat shock 42°C, 20' 24 hs 
Induces 
SGs early, 
may 
induce PBs 
later 
Cells adapt and SGs 
can disappear 
within one hour 
UV-light 
312 nm 
(UVB), 1' 
30' 
Induces 
SGs 
/ 
Aminoacid starvation 
DMEM with 4.5 g/l glucose 
and NaHCO3, without 
Methionine, Cysteine and 
Glutamine 
48 hs / 
Induces 
SGs 
/ 
Hypoxia 
Cobalt(II) chloride, CoCl2 
200-400 µM, 
12-24 hs 
/ 
Induces 
both SGs 
and PBs 
/ 
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DISCUSSION 
 
RNASET2 is an atypical tumor suppressor gene. In our recent works we have 
demonstrated that RNASET2 overexpression in ovarian cancer cells is 
associated with a strong suppression of their tumorigenicity in vivo, without 
affecting any in vitro cancer-related growth parameter (Acquati, 2005) 
(Acquati, 2011). Noteworthy, the control of tumor growth apparently relies on 
the establishment of a cross-talk between RNASET2-overexpressing cancer 
cells and the tumor microenvironment, where the monocyte/macrophage 
lineage turned out to represent the most likely target of RNASET2 activity 
(Acquati, 2011). These biological properties of RNASET2 gene allowed us to 
record it as a member of the "tumor antagonizing/malignancy suppressor 
genes" class (Klein, 2009). This family of genes is characterized by an 
asymmetric tumor-suppressive activity, which is only carried out in the in vivo 
context. Central to this concept is the existence of a microenvironmental 
control of tumorigenesis (Bissell & Hines, 2011) (Nelson & Bissell, 2006).  
 
Thus, the first and principal aim of my Ph.D. project was to further investigate 
the putative occurrence of a functional cross-talk between extracellular 
RNASET2 protein and immunocompetent cells. This could be achieved by 
means of at least two different mechanisms, which represent my working 
hypothesis: (i) an indirect course of action by the RNASET2-overexpressing 
cancer cell, which involves the production and secretion of signaling molecules 
endorsed with immunological functions, or (ii) a direct interaction between 
secreted RNASET2 protein and immunocompetent cells.  
As for the first hypothesis, some important premises must be taken into 
account in order to correctly interpret my experimental choices.  
We have recently demonstrated that RNASET2-overexpressing ovarian tumor 
Hey3Met2 cells were strongly inhibited in their tumorigenic potential in vivo, 
but they showed no differences in cancer-related growth parameters in vitro 
when compared to control cells. More in detail, we have assessed the 
following five in vitro assays: proliferation rate, colony formation, cell 
adhesion, anchorage-independent growth and apoptotic rate (Acquati, 2011). 
By contrast, a consistent infiltration of host immune cells was observed in 
xenograft tumors derived from the injection of RNASET2-overexpressing 
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Hey3Met2 cells (Acquati, 2011). Within this conceptual and experimental 
framework, we have therefore attributed to the RNASET2 gene a non-cell 
autonomous role for tumor suppression and tentatively set aside the 
possibility that RNASET2 could exert its antitumoral function in a cell 
autonomous way. Consequently, we decided to perform an in vitro microarray 
gene expression analysis in order to compare RNASET2-overexpressing 
Hey3Met2 clones with control clones. The rationale for this assay was to look 
for changes in the expression levels of signaling molecules involved in innate 
immunity in RNASET2-overexpressing tumor cells. On the other hand, this 
assay had the potential to investigate at a deeper level the occurrence of 
putative cell-autonomous roles for RNASET2, which could still not be 
completely rule out, due to the limited range of in vitro assays previously 
carried out. Indeed, a solid body of evidence from two RNASET2 orthologues, 
namely Rny1p from S. cerevisiae and ACTIBIND from A. niger, has recently 
demonstrated that important RNASET2-mediated processes actually take place  
within cells (Thompson, 2009) (Roiz, 2006). 
As the experimental data showed, no changes were observed in the in vitro 
expression pattern of genes involved in innate immunity. In the context of a 
non-cell autonomous model for RNASET2-mediated tumor suppression, this 
peculiar result is prone to two different interpretations: (i) the hypothesis of an 
indirect role of RNASET2 protein in in vivo tumor suppression could still be 
plausible, but not detectable by the microarray technology in the present 
experimental setting, which was carried out in cells cultured in vitro, or (ii) a 
direct role of extracellular RNASET2 in tumor suppression should be 
envisioned. 
Within this frame, using an opposite and complementary in vivo experimental 
model, our research group has recently gathered evidence strongly supporting 
the latter interpretation. More in detail, using an RNA-interference approach 
we have established a total abolition of RNASET2 expression in the poorly 
tumorigenic human ovarian cancer cell line OVCAR3. Following the injection of 
RNASET2-silenced OVCAR3 cells in nude mice, we have observed the 
appearance of tumor masses significantly larger than those observed after 
injection of control OVCAR3 cells. Interestingly, when an in vivo analysis of the 
gene expression profile for human genes was performed on xenograft tumors, 
a significant change in the expression levels of genes involved in leukocytes 
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activation was observed. Moreover, when the same analysis was performed in 
order to investigate the expression profile for mouse genes, significant changes 
in gene categories such as "immune response", "defense response", "innate 
immune response" and "acute inflammatory response" were recorded 
(Acquati 2012, submitted).  
As long as the occurrence of a putative cell autonomous role for RNASET2 is 
concerned, the microarray hybridization assay unveiled sixty-five genes which 
turned out to be modulated by RNASET2. We thus selected among these genes 
a set of thirteen candidates on the basis of their involvement in cancer-related 
processes and we further validated expression changes by RT-qPCR, in both 
the in vitro and the in vivo contexts. The qPCR analysis thus confirmed the 
pattern of gene expression changes for most tested genes in vitro. By contrast, 
the RNASET2-mediated changes in the expression levels of the thirteen genes 
that we have observed in vitro were not confirmed in xenograft tumors, with 
the exception of LIMCD1, DSE and RELB genes.  
Thus, these three genes represent bona fide candidate effector genes for 
RNASET2-mediated tumor suppression in vivo and are worth to be analysed in 
depth. Interestingly, two of them (RELB and DSE) show a plausible link with 
cellular functions related to tumor rejection by the immune system. RELB 
gene, in fact, is involved in the NF-kB pathway and is clearly associated with 
adaptive immune responses mediated by dendritic cells (Clark G. J., 1999). This 
is particularly interesting in the light of a recent work demonstrating a role for 
the omega-1 T2 ribonuclease from Schistosoma mansoni in priming dendritic 
cells for Th2 polarization of T-lymphocytes (Steinfelder, 2009). As for the DSE 
gene, it was originally identified on the basis of the ability of its protein 
product to be recognized with high efficiency by a subset of cytotoxic T-
lymphocytes in certain tumors (Nakao, 2000).  
Finally, LIMCD1 gene encodes for a poorly characterized protein involved in 
cardiac hypertrophy (Frank, 2010); however, the related LIMD1 gene has been 
recently reported to display functional properties reminiscent of tumor 
antagonizing genes (Klein, 2007). Taken together, the gene expression profiling 
data seem to provide a support for the hypothesis that the RNASET2-mediated 
tumor suppression observed in vivo is likely mediated by a direct, non-cell 
autonomous role. 
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In my opinion, these data deserve some general comments concerning the 
relevance of the methodological approach employed in the investigation of an 
experimental subject. In fact, the higher the sensitivity of the method 
employed, the higher the amount of information that we can obtain. And this 
is not a merely quantitative problem. Indeed, employing five different in vitro 
experimental assays we have observed no differences between RNASET2-
overexpressing tumor cells and control tumor cells and we have reasonably 
concluded that RNASET2 gene behaves as a tumor antagonizing gene, acting in 
an asymmetric non-cell autonomous way. By contrast, employing the much 
more sensitive microarray/qPCR approach we have uncovered three genes 
that showed a congruent change in the expression pattern between the in 
vitro and the in vivo settings and whose function could be important in 
RNASET2-mediated tumor suppression. This finding is in sharp contrast with 
the asymmetric nature of tumor suppressive function attributed to tumor 
antagonizing genes.  
Thus, is RNASET2 gene a tumor antagonizing/malignancy suppressor gene? 
Maybe the right answer is that the strict categorization of a gene within a 
particular class is like putting the gene within a sealed cage. In my opinion, a 
more reasonable classification of genes could be represented by a cage with an 
open door, from which genes could either enter or go out depending on the 
experimental approach that we employ to investigate their function. What is 
objectively documented is the fact that RNASET2 gene is endowed with a 
strong antitumor activity, both related to and dependent on the tumor 
microenvironment context.  
 
Being the tumor microenvironment so important in the RNASET2-mediated 
tumor suppression in vivo, I decided to focus my investigation on the issue of a 
direct interaction between the RNASET2 protein and innate immune cells. This 
hypothesis is supported by two main observations: (i) the RNASET2 protein is 
secreted from cells in the extracellular space, where a direct interaction with a 
target cell could occur, and (ii) the recruitment and functional activation of 
immunocompetent cells belonging from the monocyte-macrophage lineage is 
necessary for the RNASET2-mediated tumor suppression to occur in vivo 
(Acquati, 2011). 
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Searching for an RNASET2 target cell, I started anyway my experimental 
investigations performing cell surface binding assays on tumor cells, as they 
were easily available in the laboratory and as we can reasonably hypothesize 
the existence of a common binding/internalization pathway for RNASET2 
protein, which could be cell-type independent. Thus, to our aim tumor cells, 
which are known to express a wide range of transmembrane receptor proteins 
for different types of signaling molecules (Hanahan, 2011), could represent an 
adequate experimental model.   
Thus, using three different in vitro experimental approaches I was able to 
demonstrate that endogenously-produced RNASET2 protein could bind the 
tumor cell surface. Moreover, using the previously described RNASET2-
silenced OVCAR3 cell model, I have also observed that exogenously-provided 
RNASET2 protein could be internalized following the binding to the tumor cell 
surface.  
 
On the basis of these encouraging results, I decided to focus my investigation 
on the cell-type which could more likely represent the target of the RNASET2 
protein tumor suppressive function: immunocompetent cells, particularly 
those belonging to the monocyte-macrophage lineage. To shed light on this 
issue, I have first investigated the cell surface binding of exogenously-provided 
RNASET2 protein on both native and M1/M2 polarized human macrophages, 
where the latter are known to exert an anti- and pro-tumor function within the 
tumor microenvironment context, respectively (Galdiero, 2012). As a result, a 
dose-dependent RNASET2 binding to the cell surface was detected.  
Thus, it is tempting to hypothesize the existence of a cell surface receptor for 
RNASET2 protein in innate immune cells. Within this frame, enlightening new 
evidences have been very recently collected by Everts et al. concerning the 
omega-1 T2 ribonuclease secreted by Schistosoma mansoni eggs, which has 
recently been shown to condition mammalian dendritic cells to prime Th2 
responses (Steinfelder, 2009). Mechanistically, the researchers have 
demonstrated that omega-1 protein is bound and internalized via its glycans by 
the mannose receptor and subsequently impairs protein synthesis by 
degrading both rRNAs and mRNAs (Everts, 2012). Being human RNASET2 
protein also glycosylated, one of our next aims would be the investigation of a 
similar mechanism in human macrophage cells.  
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Another recent finding concerning the fine structural characterization of 
human RNASET2 protein, which has been performed by Thorn and colleagues, 
deserves some comments. Indeed, a potential tumor necrosis factor receptor-
associated factor 2 (TRAF2) binding motif has been identified in positions 222-
225 (PKQE). TRAF2 motif is known to bind the TNFα receptor and modulate 
TNFα action on the MAP kinase and NF-kB pathways (Thorn, 2012). 
Intriguingly, this motif could either represent an additional possibility for 
RNASET2 to enter the cell or could play a putative role in protein-protein 
contacts mediated by RNASET2. 
 
The observed RNASET2 protein binding to macrophage cells strongly suggests 
that RNASET2 protein could be endowed with a chemotactic role in recruiting 
immunocompetent cells at the tumor site. To shed light on this issue, I decided 
to perform in vitro migration assays on human primary monocytes. Using 
increasing concentrations of recombinant endotoxin-free human RNASET2 
protein as a chemoattractant, I obtained migration responses reminiscent of a 
bell-shaped curve, which is the expected trend for a chemokine whose binding 
to the cell surface is receptor-mediated. Because of the high variability 
recorded in performing migration assays on primary monocytes, I decided to 
employ a promyelocitic cell line model (U937 cl.10 cells) for chemotaxis assays. 
Thus, I have performed migration assays on U937 cl.10 cells using both wild-
type and catalytically inactive H65/118F recombinant human RNASET2 protein, 
produced both in BEVS and in Pichia pastoris heterologous expression systems. 
As a result, I have observed a consistent migration in response to both the 
form of RNASET2 protein.  
In my opinion, this is a very intriguing result. In fact, these data demonstrate 
that the catalytic activity of RNASET2 protein is totally dispensable for its 
chemotactic function, as we have previously demonstrated to occur for the in 
vivo tumor suppressive activity. This evidence has important outcomes, both 
experimental and theoretical.  
Firstly, among the different in vitro experimental approaches that we have 
employed in the investigation of RNASET2 anti-tumor activity, chemotaxis 
assays are the first in which we have been able to observe results in a totally 
congruent fashion with those obtained in vivo. Within this frame, chemotaxis 
assays could represent a solid experimental tool for further in vitro 
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investigation of the RNASET2-mediated tumor suppression that occurs in the in 
vivo context.  
Secondly, the apparently dispensable catalytic activity for functional behavior 
of RNASET2 suggests that this protein could be included in the class of 
"moonlighting proteins". As proposed by Jeffery in 1999, the "one gene-one 
protein-one function" theory must be carefully revised, since an increasing 
number of proteins are being identified as multifunctional. Moonlighting 
proteins form a special class of multifunctional proteins: they perform multiple 
autonomous and unrelated functions, often without partitioning these 
functions into different protein domains. Striking examples are enzymes, which 
in addition to their catalytic function are involved in fully unrelated processes 
such as autophagy, protein transport or DNA maintenance (Jeffery, 1999). The 
human RNASET2 ribonuclease seems to behave in this way. 
 
Since the RNASET2 protein proved to directly interact with monocyte-
macrophage cells and also showed a chemotactic activity on this cell 
population, I decided to start to investigate the occurrence of a receptor-
mediated binding of the RNASET2 protein to the target cell surface. 
Intracellular signaling pathways in response to chemokines are in most cases 
triggered by the binding of the signaling molecule to a cell-surface G-protein 
coupled receptor (GPCR) (Murphy, 1994). On the basis of this information, I 
decided to perform migration assays on U937 cl.10 cells following pre-
treatment with pertussis toxin (PTx), which is known to inhibit the GPCRs 
function by means of ADP-ribosylation of Gi proteins (Schratzberger, 1996). As 
a result, PTx pre-treatment drastically impaired U937 cl.10 cells migration in 
response to recombinant wild-type human RNASET2 protein, thus confirming 
the hypothesis of a receptor-mediated cell surface binding between the 
RNASET2 protein and the target cell. 
 
As a final remark concerning this first part of my Ph.D. project, I think it is 
reasonable to propose that RNASET2 could exert its tumor-antagonizing role 
by means of a direct receptor-mediated interaction with the monocyte-
macrophage cell population. Consequently, the recruitment and the functional 
activation of such cells within the tumor microenvironment could be 
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responsible for the RNASET2-mediated tumor suppression that we have 
demonstrated to occur in vivo. 
 
In spite of the large amount of data that we have gathered demonstrating the 
RNASET2 activity in controlling tumor suppression, we have very little 
knowledge concerning the RNASET2 protein sub-cellular trafficking. This is not 
an irrelevant issue, since a deeper investigation of these aspects of RNASET2 
biology could allow us to get more insights into putative cell autonomous 
functions of this moonlighting protein.  
In order to start to investigate this issue, we took advantage of some data that 
we have recently collected concerning the subcellular co-localization of 
RNASET2 protein with processing-bodies (PBs) markers (Vidalino, 2012). PBs 
are transient cytoplasmic structures mainly associated with the mRNA decay 
process, which are induced by cellular stress (Kedersha & Anderson, 2007). 
Interestingly, it has been recently demonstrated that PBs are spatially, 
compositionally and functionally linked to stress granules (SGs), which 
represent cytoplasmic aggregates of stalled translational pre-initiation 
complexes that accumulate in cells during stress (Kedersha, 2005).  
Moreover, an important function in general stress-response mechanisms has 
been demonstrated for several members of the T2 family of RNases. Indeed, 
RNS2 from Arabidopsis thaliana is essential for rRNAs recycling in conditions of 
nutritional stress (Hillwig, 2010). Similarly, yeast Rny1p is released from 
vacuoles in response to oxidative stress and has a fundamental role in tRNAs 
decay (Thompson, 2009). Being the T2 ribonucleases stress-response role so 
highly conserved throughout the phyla, we reckoned that a similar function 
could be hypothesized for mammalian cells as well.  
On the basis of these experimental and theoretical premises, the second aim 
of my Ph.D. project has been the investigation of the putative role of human 
RNASET2 protein in general stress-response processes. 
To this end, I have challenged different tumor cell lines with a variety of stress-
inducing chemicals or treatments and then I have first examined changes in 
RNASET2 protein expression levels. As a result, I have observed significantly 
higher RNASET2 protein levels in treated cells, in response to different 
stresses. Particularly, I have shown that the overexpression of a specific form 
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of RNASET2 protein (36 kDa, 31 kDa or 27 kDa) was typically observable in 
response to different stress inductions.  
According to this descriptive observation, I have deeply investigated the 
functional significance of the observed RNASET2 increase in response to stress, 
particularly in the context of P-bodies dynamics. As a result, I have detected a 
marked co-localization signal for RNASET2 and DCP1 proteins in CoCl2-treated 
SKOV3 cells when compared to the untreated cells, thus confirming RNASET2 
protein as a novel component of P-bodies. 
Finally, I have better investigated the functional role of RNASET2 protein in 
RNA metabolism employing the RNASET2 knock-down experimental model 
that we have obtained in the human ovarian cancer cell line OVCAR3. Within 
this experimental framework, I was able to detect a significant increase in P-
bodies number and size in RNASET2-silenced OVCAR3 clones when compared 
to control clones. Therefore, using the same experimental approach, I have 
detected changes in SGs sub-cellular signal in the same direction as for PBs. A 
possible explanation for the observed findings could be that cells lacking 
RNASET2 have a basal cellular stress level higher than cells in which RNASET2 
protein is normally expressed. 
 
Taken together, these results are very interesting and in my opinion deserve 
some comments.  
First, both the 31 kDa and the 27 kDa isoforms of RNASET2 protein, which 
originate from proteolytic cleavages at the C-terminus of the full-length 36 kDa 
protein, are exclusively intracellular forms that likely reside within lysosomes 
(Campomenosi, 2006). The stress-induced overexpression of these RNASET2 
protein isoforms indicates a likely cell autonomous role of the RNASET2 
protein in stress response which could rely on its catalytic activity and could be 
reminiscent of the mechanism recently described to occur in the yeast 
Saccharomyces cerevisiae. Indeed, in response to oxidative stress the Rny1p T2 
ribonuclease is released from yeast vacuole into the cytosol, where it cleaves 
tRNAs (Thompson, 2009). Since it has been demonstrated that human 
lysosomal proteins are also released into the cytosol following oxidative stress 
(Guicciardi, 2004), we could postulate the existence of a similar mechanism 
involving RNASET2 protein in mammalian cells. Thus, an indepth investigation 
of this issue is among our next experimental aims. 
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A second important consideration brings the discussion back to the non-cell 
autonomous role of RNASET2 in tumor suppression and suggests a link 
between the stress response role and the antitumor activity of this gene. In 
fact, we have also observed an increase in the expression and secretion of the 
full-length 36 kDa protein following specific stress-inducing stimuli such as 
CoCl2 treatment, which induces chemical hypoxia. It is well-known that, in 
order to grow and establish a solid tumor mass, single tumor cells have to 
develop the ability to counteract different kinds of physical, mechanical and 
chemical stresses, for instance hypoxia. Within this complex frame, it is 
tempting to postulate that RNASET2 protein could act as a stress "sensor" 
during tumor development. Indeed, in the early stages of tumor progression 
RNASET2 protein might be induced and secreted by the cancer cell in the 
extracellular space, where it might act as an "ALARMIN". The term "alarmin" 
was coined by Oppenheim and Yang in order to identify a heterogeneous class 
of molecules, which (i) are released and/or secreted by cells in response to 
danger and (ii) are endowed with the ability to alert innate and adaptive 
immune defense mechanisms. Interestingly, this molecules tipically display 
both chemotactic and activating effects on antigen presenting cells (APCs), 
such as dendritic cells and macrophages (Oppenheim & Yang, 2005).  
Strongly supporting our hypothesis of an alarmin function for RNASET2 protein 
during tumor development are some recent data demonstrating that the 
RNASET2 transcript levels are tipically higher in early stages tumors than in 
later stages tumors (unpublished results of our group).  
 
Thus, as final remarks concerning this second part of my Ph.D project, it might 
be argued that human RNASET2 could play a cell autonomous role in 
orchestrating defense mechanisms against stress conditions, as epitomized by 
both the overexpression of the intracellular forms of RNASET2 protein in 
response to stress and the co-localization with PBs marker proteins.  
On the other hand, at the higher complex tumor microenvironment level, 
human RNASET2 could act as an alarmin, which could be overexpressed and 
secreted during the early stages of tumor progression in order to activate 
innate immune defense mechanisms against the tumor.  
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